Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis
NCT ID: NCT03113721
Last Updated: 2019-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
571 participants
OBSERVATIONAL
2017-03-27
2019-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
IMproved PREdiction of Severe Sepsis in the Emergency Department
NCT01392508
Sepsis Assessment in Belgian Emergency Rooms
NCT02424721
Heparin Binding Protein in Early Sepsis Diagnosis
NCT03295825
Evaluation of the Heparin Binding Protein Levels in Sepsis
NCT02533011
Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
NCT03682003
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The secondary objectives of this study are to separately evaluate the performance of HBP concentration to a) indicate the presence of severe sepsis (including severe sepsis) at admission and b) to predict the outcome of severe sepsis (including septic shock) over 72 hours, in patients with suspected infection following emergency department admission.
Further exploratory objectives include evaluating the use of HBP measurement to indicate the outcome of severe sepsis (including septic shock) in patients with suspected infection 12-24 hours after emergency department admission, to compare the use of HBP to other markers of severe infection and to evaluate whether or not different cut-off values are required for the progression and outcome measures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Drexel University
OTHER
York Hospitals
OTHER
Jefferson Medical College of Thomas Jefferson University
OTHER
Vanderbilt University Medical Center
OTHER
Baylor College of Medicine
OTHER
Axis Shield Diagnostics Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theodore Corbin, MD
Role: PRINCIPAL_INVESTIGATOR
Drexel University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Drexel University
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
York Hospitals
York, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEP-FMHBP-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.